Journal: Frontiers in Immunology

Article Title: The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease

doi: 10.3389/fimmu.2026.1758367

Figure Lengend Snippet: Intergroup comparison of CCL23 protein expression among the Kawasaki disease (KD) group, fever control (FC) group, and healthy control (HC) group.

Article Snippet: Meanwhile, the quantitative detection of CCL23 protein was conducted using the Human CCL23 ELISA Kit (Boster Biological Technology, Product No.: EK1224) in strict accordance with the kit instructions.

Techniques: Comparison, Expressing, Control

Journal: Frontiers in Immunology

Article Title: The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease

doi: 10.3389/fimmu.2026.1758367

Figure Lengend Snippet: Diagnostic accuracy analysis of CC Chemokine Ligand 23 (CCL23) for Kawasaki disease (KD). (A) Comparison between the KD group and the fever control (FC) group; (B) Comparison between the KD group and the healthy control (HC) group; (C) Comparison between the KD group and the combined FC and HC groups.

Article Snippet: Meanwhile, the quantitative detection of CCL23 protein was conducted using the Human CCL23 ELISA Kit (Boster Biological Technology, Product No.: EK1224) in strict accordance with the kit instructions.

Techniques: Diagnostic Assay, Comparison, Control

Journal: Cancers

Article Title: Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

doi: 10.3390/cancers17243925

Figure Lengend Snippet: CCL23 is present in all human ascites samples with primary or recurrent ovarian cancer. ( A ) The distribution of CCL23 concentration (ng/mL) in ovarian cancer ascites samples ( n = 40). ( B ) Low ( n = 17), intermediate ( n = 12), and high ( n = 11) CCL23 ascites concentrations. Data presented as mean ± S.E.M. ANOVA with Bonferroni post hoc test performed for significance; * p < 0.05. ( C ) Kaplan–Meier survival curves (log-rank) of patient outcome data from low ( n = 17; gray line), intermediate ( n = 12; light gray line), and high ( n = 11; red line) CCL23 concentrations.

Article Snippet: Cell-free supernatant was harvested from serum-starved cells incubated with vehicle, CCL23 aa22-120 (Peprotech, East Windsor, NJ, USA; 300-29) or CCL23 aa46-120 (R&D Systems, Minneapolis, MN, USA; 131-M1-025) peptides for 30 min, or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM; Tocris; Minneaoplis, MN, USA; 4655) was reconstituted and serum-starved cells were incubated with 100 μM NSC 74859 for 30 min [ ] prior to incubation with CCL23.

Techniques: Concentration Assay

Journal: Cancers

Article Title: Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

doi: 10.3390/cancers17243925

Figure Lengend Snippet: High CXCL10 levels correlate with low CCL23 concentrations in ovarian ascites. ( A ) Quantification of C-X-C Motif Chemokine Ligand 10 (CXCL10) cytokine concentration from ovarian ascites patient samples containing low ( n = 17), intermediate ( n = 12), and high ( n = 11) CCL23. Data presented as mean ± S.E.M. Statistical analyses performed using one-way ANOVA with Dunnet’s post hoc test for significance; * p < 0.05. ( B ) Pearsons linear regression of CXCL10 versus CCL23 concentrations indicated a significant negative association between (F(1,38) = 4.86, p = 0.033).

Article Snippet: Cell-free supernatant was harvested from serum-starved cells incubated with vehicle, CCL23 aa22-120 (Peprotech, East Windsor, NJ, USA; 300-29) or CCL23 aa46-120 (R&D Systems, Minneapolis, MN, USA; 131-M1-025) peptides for 30 min, or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM; Tocris; Minneaoplis, MN, USA; 4655) was reconstituted and serum-starved cells were incubated with 100 μM NSC 74859 for 30 min [ ] prior to incubation with CCL23.

Techniques: Concentration Assay

Journal: Cancers

Article Title: Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

doi: 10.3390/cancers17243925

Figure Lengend Snippet: In silico analysis of patient outcomes differs based on tumor expression levels of CCL23 and CXCL10. Kaplan–Meier overall survival analyses were performed on stage III and IV ovarian cancer patients, histology agnostic ( n = 1081, http://kmplot.com ), using datasets hosted in the Cancer Genome Atlas (TCGA). Patients were stratified based on the quantile expression of high (red line) versus low (black line) ( A ) CCL23 mRNA or ( B ) CXCL10 mRNA expression from ovarian tumors. Log-rank and Cox hazards tests were performed for statistical significance.

Article Snippet: Cell-free supernatant was harvested from serum-starved cells incubated with vehicle, CCL23 aa22-120 (Peprotech, East Windsor, NJ, USA; 300-29) or CCL23 aa46-120 (R&D Systems, Minneapolis, MN, USA; 131-M1-025) peptides for 30 min, or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM; Tocris; Minneaoplis, MN, USA; 4655) was reconstituted and serum-starved cells were incubated with 100 μM NSC 74859 for 30 min [ ] prior to incubation with CCL23.

Techniques: In Silico, Expressing

Journal: Cancers

Article Title: Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

doi: 10.3390/cancers17243925

Figure Lengend Snippet: In vitro stimulation of immune cells with CCL23 reduces CXCL10 secretion. ( A ) Immunohistochemical staining of differentiated THP-1 monocytes for the C-C motif chemokine receptor 1 (CCR1; red); nuclei stained with DAPI (blue). Scale bar = 200 μm. ( B ) Secondary antibody only staining control. ( C ) qRT-PCR assessment of gene expression for CCR1 in HEL ( n = 3) and THP-1 cells ( n = 3). ( D ) Quantification of C-X-C Motif Chemokine Ligand 10 (CXCL10) cytokine concentrations from cell-free supernatant of treated THP-1 cells represented as fold-change normalized to vehicle control ( n = 3 per group). Cells were stimulated with either vehicle, CCL23 peptides (aa22-120 and aa46-120; 100 ng/mL, 30 min), or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM) followed by CCL23. Data presented as mean ± S.E.M., n = 3 separate experiments. Statistical analyses performed using t -test or one-way ANOVA with Bonferroni post hoc test for significance; * p < 0.05.

Article Snippet: Cell-free supernatant was harvested from serum-starved cells incubated with vehicle, CCL23 aa22-120 (Peprotech, East Windsor, NJ, USA; 300-29) or CCL23 aa46-120 (R&D Systems, Minneapolis, MN, USA; 131-M1-025) peptides for 30 min, or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM; Tocris; Minneaoplis, MN, USA; 4655) was reconstituted and serum-starved cells were incubated with 100 μM NSC 74859 for 30 min [ ] prior to incubation with CCL23.

Techniques: In Vitro, Immunohistochemical staining, Staining, Control, Quantitative RT-PCR, Gene Expression

Journal: Frontiers in Immunology

Article Title: The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease

doi: 10.3389/fimmu.2026.1758367

Figure Lengend Snippet: Intergroup comparison of CCL23 protein expression among the Kawasaki disease (KD) group, fever control (FC) group, and healthy control (HC) group.

Article Snippet: Meanwhile, the quantitative detection of CCL23 protein was conducted using the Human CCL23 ELISA Kit (Boster Biological Technology, Product No.: EK1224) in strict accordance with the kit instructions.

Techniques: Comparison, Expressing, Control

Journal: Frontiers in Immunology

Article Title: The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease

doi: 10.3389/fimmu.2026.1758367

Figure Lengend Snippet: Diagnostic accuracy analysis of CC Chemokine Ligand 23 (CCL23) for Kawasaki disease (KD). (A) Comparison between the KD group and the fever control (FC) group; (B) Comparison between the KD group and the healthy control (HC) group; (C) Comparison between the KD group and the combined FC and HC groups.

Article Snippet: Meanwhile, the quantitative detection of CCL23 protein was conducted using the Human CCL23 ELISA Kit (Boster Biological Technology, Product No.: EK1224) in strict accordance with the kit instructions.

Techniques: Diagnostic Assay, Comparison, Control

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: CCL23 expression is induced by IL-4 in a STAT6-dependent fashion.

doi: 10.4049/jimmunol.178.7.4335

Figure Lengend Snippet: FIGURE 1. CCL23 induction in monocytes. A rep- resentative experiment of 10 is shown. A, CCL23 steady-state mRNA expression in monocytes is depicted relative to the housekeeping gene EF1-. B, GM-CSF synergizes with IL-4 but not with IL-13 to stimulate CCL23 expression in monocytes. Error bars, SDs. C, Time course of IL-4- and GM-CSF-induced CCL23 RNA and protein expression by monocytes. Error bars, SDs.

Article Snippet: As standard, recombinant CCL23, aa 22–120 was used (R&D Systems).

Techniques: Expressing

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: CCL23 expression is induced by IL-4 in a STAT6-dependent fashion.

doi: 10.4049/jimmunol.178.7.4335

Figure Lengend Snippet: FIGURE 2. A, The schematic structure of four dif- ferent CCL23 promoter reporter gene constructs is shown. The numbers refer to the number of nucleotides relative to the start site of transcription (bent arrow). TATA indicates the minimal promoter from the mouse -globin gene linked to the firefly luciferase reporter (Luc). The black box marks the position of the STAT6 site. The nucleotide sequence of the STAT6 site in the CCL23 promoter is shown along with known STAT6 sites from the eotaxin-3 and the IgE germline promoter. Shaded nucleotides highlight and the two arrows indi- cate the position of the inverted repeat triplet in the STAT6 site. B, IL-4 inducibility of CCL23 reporter plasmids in transiently transfected HEK293 cells. The induction factor represents the ratio of luciferase ex- pression in IL-4-treated vs uninduced cells. One repre- sentative experiment of four is shown.

Article Snippet: As standard, recombinant CCL23, aa 22–120 was used (R&D Systems).

Techniques: Construct, Luciferase, Sequencing, Transfection

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: CCL23 expression is induced by IL-4 in a STAT6-dependent fashion.

doi: 10.4049/jimmunol.178.7.4335

Figure Lengend Snippet: FIGURE 3. The CCL23 STAT6 site is required for IL-4 induction of the CCL23 promoter. Top, The schematic structure of the CCL23p-XE re- porter plasmid is shown. The black box denotes the position of the STAT6 site. Below, the sequence of the wild-type (CCL23p-XE) and mutated STAT6 site (CCL23p-XEmut) is indicated. Left graph, The IL-4 response of the two CCL23 promoter plasmids. Right graph, The cytokine induc- ibility of the STAT6 site in the absence of additional CCL23 promoter elements. One representative of six experiments is shown.

Article Snippet: As standard, recombinant CCL23, aa 22–120 was used (R&D Systems).

Techniques: Plasmid Preparation, Sequencing

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: CCL23 expression is induced by IL-4 in a STAT6-dependent fashion.

doi: 10.4049/jimmunol.178.7.4335

Figure Lengend Snippet: FIGURE 4. STAT6 protein interacts with its binding site in IL-4-in- duced monocytes. EMSA using STAT6 binding site containing double- stranded oligonucleotides from the eotaxin-3 or the CCL23 promoter as probes. The numbers indicate the molar excess of competitor oligonucle- otides relative to the radiolabeled probe. The position of the STAT6-con- taining nucleoprotein complex is shown.

Article Snippet: As standard, recombinant CCL23, aa 22–120 was used (R&D Systems).

Techniques: Binding Assay

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: CCL23 expression is induced by IL-4 in a STAT6-dependent fashion.

doi: 10.4049/jimmunol.178.7.4335

Figure Lengend Snippet: FIGURE 5. Fine mapping of the negative regulatory cis-acting element. Top, The schematic structures of four CCL23 promoter reporter constructs is shown. The nucleotide sequence shown indicates the negative regulatory element. Below, The left graph demonstrates the IL-4 response of the four promoter plasmids. Right graph, The effect of the negative element on cytokine induction of the eotaxin-3 and the IgE germline promoter. One representative of three experiments is shown. Statistical significance was determined using a Student two-tailed t test for pairs.

Article Snippet: As standard, recombinant CCL23, aa 22–120 was used (R&D Systems).

Techniques: Construct, Sequencing, Two Tailed Test

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: CCL23 expression is induced by IL-4 in a STAT6-dependent fashion.

doi: 10.4049/jimmunol.178.7.4335

Figure Lengend Snippet: FIGURE 6. CCL23 immunoreactivity in skin of normal human subjects (C) and lesional skin of atopic dermatitis patients (B and D). D, An enlarged image of the region marked by the rectangle in B. Arrows, The position of CCL23-immunoreactive cells. A, Isotype control staining of atopic skin. One representative donor of three is shown.

Article Snippet: As standard, recombinant CCL23, aa 22–120 was used (R&D Systems).

Techniques: Control, Staining